MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Myoclonus in a Large Urban Center: 10 Year Experience

    K. Oh, M. Hamed, H. Sarva, D. Victor (New York, USA)

    Objective: To describe various forms of myoclonus in admitted patients in a 10-year period. Background: Myoclonus consists of brief, shock-like involuntary movements. It may occur…
  • 2022 International Congress

    Defining nomenclature and age cut off for Early Onset Parkinson’s Disease: Recommendations from the Early Onset Parkinson’s Disease Task Force.

    R. Mehanna, K. Smilowska, A. Merola, B. Zhang, B. Post, C. Marras, J. Fleisher, K. Kumar, M. Salari, O. Ross, R. Alcalay, T. Hatano, V. Mcconvey, Y-R. Wu, E-K. Tan, R. Savica (Houston, USA)

    Objective: To define the nomenclature for Early Onset Parkinson Disease (EOPD) / Young Onset Parkinson Disease (YOPD), and the age at onset (AAO) cut off…
  • 2022 International Congress

    To be or not to bupropion: a drug-induced parkinsonism?

    A. Silva, J. Pinto, M. Gago, M. Rodrigues (Braga, Portugal)

    Objective: To draw attention to drug-induced parkinsonism. Background: Although the main causes of parkinsonism are degenerative, there are some reversible causes, including drug-induced parkinsonism. Method:…
  • 2022 International Congress

    Epileptic seizures in patients with parkinsonism: experience of a tertiary centre

    C. Azoia, R. Jesus, A. Costa, A. Velon, P. Guimarães (Vila Real, Portugal)

    Objective: We aim to evaluate seizure frequency in patients with parkinsonism in a tertiary centre. Background: Observational studies suggest that the prevalence of epilepsy in…
  • 2022 International Congress

    Clinical, imaging and genetic profile of patients with NBIA spectrum disorders

    N. Sriram, P. Pal, V. Holla, N. Kamble, J. Saini, R. Yadav, RAJ. Battu, VY. K N, B. Muthusamy, RI. Kumari (Bangalore, India)

    Objective: To describe the clinical, imaging and genetic profile of patients with suspected NBIA disorders Background: NBIA disorders are clinically, radiologically and genetically heterogenous group…
  • 2022 International Congress

    The impact of Parkinson’s disease on multifactorial aspects of attention

    O. Peleg, Z. Ktzir, I. Maidan, D. Levy, A. Mirelman (Tel Aviv, Israel)

    Objective: (1) To characterize the differential effects of PD on the two attentional networks and (2) To examine the ability of attentional measurements differentiate between…
  • 2022 International Congress

    sleep disturbance and wakefulness in parkinson’s disease

    A. Tohirjonova, м. Tohirjonov (Tashkent, Uzbekistan)

    Objective: a complete study of sleep disorders and their adequate treatment Background: Sleep and wake disturbances are the second most common non-motor symptom of Parkinson's…
  • 2022 International Congress

    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations

    J. Agin-Liebes, R. Hickman, J. Vonsattel, X. Flowers, P. Faust, R. Mayeux, K. Marder, S. Przedborski, S. Fahn, M. Surface, R. Alcalay (New York, USA)

    Objective: To systematically examine the Columbia University LRRK2 brain bank for TDP-43 deposits Background: LRRK2 G2019S mutations have been associated with parkinsonism and a wide range of…
  • 2022 International Congress

    Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease

    L. Batzu, S. Rota, A. Hye, A. Heslegrave, D. Trivedi, L. Gibson, C. Farrell, P. Zinzalias, A. Rizos, H. Zetterberg, K. Ray Chaudhuri, D. Aarsland (London, United Kingdom)

    Objective: To investigate the association of plasma p-tau181 and NfL with cognitive performance and cognitive progression in PD patients. Background: Cognitive impairment (CI) is a…
  • 2022 International Congress

    Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612

    A. Espay, A. Ellenbogen, T. Gurevich, R. Case, L. Adar, T. Yardeni, L. Salin (Cincinnati, USA)

    Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…
  • « Previous Page
  • 1
  • …
  • 145
  • 146
  • 147
  • 148
  • 149
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley